Evaluation of treatment with bosentan in patients with carcinoid heart disease: Single center study

Onkologie

Volumn 33, Issue 6, 2010, Pages 300-304

  Lafaras, Christos T ^a   Mandala, Eudokia M ^a   Platogiannis, Dimitrios N ^a   Saratzis, Athanasios N ^a   Barbetakis, Nikolaos G ^a   Paraskevopoulos, Panagiotis P ^a   Ilonidis, George C ^a   Bischiniotis, Theodoros S ^a  

^a THEAGENIO CANCER HOSPITAL   (Greece)

Author keywords

Bosentan; Carcinoid heart disease; Echocardiography

Indexed keywords

ANGIOTENSIN II ANTAGONIST; BOSENTAN; BRAIN NATRIURETIC PEPTIDE; CALCIUM CHANNEL BLOCKING AGENT; CAPECITABINE; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ETOPOSIDE; FLUOROURACIL; OCTREOTIDE; SOMATOSTATIN DERIVATIVE; ANTIHYPERTENSIVE AGENT; ANTINEOPLASTIC AGENT; ENDOTHELIN RECEPTOR ANTAGONIST; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76); SULFONAMIDE;

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CARCINOID SYNDROME; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; DRUG EFFICACY; ECHOCARDIOGRAPHY; EXERCISE TEST; FEMALE; HEART RIGHT VENTRICLE FAILURE; HEART RIGHT VENTRICLE PRESSURE; HUMAN; LIVER METASTASIS; MALE; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; WALKING; BLOOD; CARCINOID HEART DISEASE; DOPPLER ECHOCARDIOGRAPHY; DRUG EFFECTS; FOLLOW UP; GASTROINTESTINAL NEOPLASMS; LUNG NEOPLASMS; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; OVARIAN NEOPLASMS; PATHOLOGY;

AGED; ANTIHYPERTENSIVE AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOID HEART DISEASE; COMBINED MODALITY THERAPY; ECHOCARDIOGRAPHY, DOPPLER; ENDOTHELIN RECEPTOR ANTAGONISTS; EXERCISE TEST; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL NEOPLASMS; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; OVARIAN NEOPLASMS; PEPTIDE FRAGMENTS; SULFONAMIDES;

EID: 77953243003     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000313596     Document Type: Article

References (26)

1. Zuetenhorst JM, Taal BG: Metastatic carcinoid tumors: a clinical review. Oncologist 2005;10:123-131.
2. Chaowalit N, Connoly HM, Schaff HV, Webb MJ, Pellikka PA: Carcinoid heart disease associated with primary ovarian carcinoid tumour. Am J Cardiol 2004;93:1314-1315.
3. The Criteria Committee of the New York Heart Association: Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels, 9th ed. Boston, MA, Little, Brown and Co, 1994, pp. 253-256.
4. Channick RN, Simonneau G, Sitbon O, Robbins IM, Frost A, Tapson VF, Badesch DB, Roux S, Rainisio M, Bodin F, Rubin LJ: Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo- controlled study. Lancet 2001;358:1119-1123. (Pubitemid 32971843)
5. Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, Pulido T, Frost A, Roux S, Leconte I, Landzberg M, Simonneau G: Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346:896-903. (Pubitemid 34984638)
6. Sitbon O, Badesch DB, Channick RN, Frost A, Robbins IM, Simonneau G, Tapson VF, Rubin LJ: Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study. Chest 2003; 124:247-254. (Pubitemid 36851359)
7. Fitzner B, Brock P, Holzhüter SA, Nizze H, Sparmann G, Emmrich J, Liebe S, Jaster R: Synergistic growth inhibitory effects of the dual endothelin-1 receptor antagonist bosentan on pancreatic stellate and cancer cells. Dig Dis Sci 2009;54:309-320.
8. Günther A, Markart P, Eickelberg O, Seeger W: Pulmonary fibrosis-a therapeutic dilemma. Med Klin 2006;101:308-312.
9. Antoniu SA: Targeting the endothelin pathway in the idiopathic pulmonary fibrosis: the role of bosentan. Expert Opin Ther Targets 2008;12:1077-1084.
10. King TE Jr: Bosentan for idiopathic pulmonary fibrosis. Curr Opin Investig Drugs 2008;9:1171-1179.
11. Moller JE, Pellica PA, BernheimAM, Schaff HV, Rubin J, Connolly HM: Prognosis of carcinoid heart disease: analysis of 200 cases over two decades. Circulation 2005;112:3320-3327.
12. Simula D, Edwards W, Tazelaar H, Connolly HM, Schaff HV: Surgical pathology of carcinoid heart disease: a study of 139 valves from 75 patients spanning 20 years. Mayo Clin Proc 2002;77:139-147.
13. Gustafsson BI, Hauso O, Drozdov I, Kidd M, Modlin IM: Carcinoid heart disease. Int J Cardiol 2008; 129:318-324.
14. Bhattacharyya S, Toumpanakis C, Caplin ME, Davar J: Analysis of 150 patients with carcinoid syndrome seen in a single year at one institution in the first decade of the twenty-first century. Am J Cardiol 2008;101:378-381.
15. Modlin I, Shapiro M, Kidd Mark: Carcinoid tumors and fibrosis: an association with no explanation. Am J Gastroenterol 1999;12:2466-2478.
16. Abi-Saleh B, Schoondyke JW, Abboud L, Downs CJ, Haddadin TZ, Iskandar SB: Tricuspid valve involvement in carcinoid disease. Echocardiography 2007;24:439-442.
17. Zaca V, Mondillo S, Focardi M, Ballo P, Giacomin E, Favilli R, Marzilli M: Right-sided heart failure in carcinoid syndrome. Int J Cardiol 2007;114:79-80.
18. Bossone E, Bodini BD, Mazza A, Allegra L: Pulmonary arterial hypertension: the key role of echocardiography. Chest 2005;127:1836-1843.
19. Robiolio PA, Rigolin VH, Wilson JS, Harrison JK, Sanders LL, Bashore TM, Feldman JM: Carcinoid heart disease. Correlation of high serotonin levels with valvular abnormalities detected by cardiac catheterization and echocardiography. Circulation 1995;92:790-795.
20. Wee CC, Phillips RS, Aurigemma G, Erban S, Kriegel G, Riley M, Douglas PS: Risk for valvular heart disease among users of fenfluramine and dexfenfluramine who underwent echocardiography before use of medication. Ann Intern Med 1998; 129:870-874.
21. Rajamannan N, Caplice N, Anthikad F, Sebo TJ, Orszulak TA, Edwards WD, Tajik J, Schwartz RS: Cell proliferation in carcinoid valve disease: a mechanism for serotonin effects. J Heart Valve Dis 2001;10:827-832.
22. Kidd M, Modlin IM, Shapiro MD, Camp RL, Mane SM, Usinger W, Murren JR: CTGF, intestinal stellate cells and carcinoid fibrogenesis. World J Gastroenterol 2007;13:5208-5216.
23. Modlin IM, Shapiro MD, Kidd M: Carcinoid tumors and fibrosis: an association with no explanation. Am J Gastroenterol 2004;99:2466-2478.
24. Bhattacharyya S, Toumpanakis C, Caplin ME, Davar J: Usefulness of N-terminal pro-brain natriuretic peptide as a biomarker of the presence of carcinoid heart disease. Am J Cardiol 2008;102: 938-942.
25. Bernheim AM, Connolly HM, Hobday TJ, Abel MD, Pellikka PA: Carcinoid heart disease. Prog Cardiovasc Dis 2007;49:439-451.
26. Gustafsson BI, Hauso O, Kidd M, Modlin IM: Carcinoid heart disease; in Modlin IM, Oberg K (eds): A Century of Advances in Neuroendocrine Tumor Biology and Treatment. Hannover, Felsenstein C.C.C.P, 2007, pp. 288-297.